*  Combination for treatment of proliferative diseases - Patent # 5744460 - PatentGenius
In other lung carcinomas, positive effects with mitomycin or cis-platin and the SEQ-ID NO: 1-ODN are found. In human breast ... mitomycin for large cell lung carcinomas; and. vinblastine for breast cancer;. are in combination; where any component a) and b ... Similarly, the combination of the SEQ-ID NO: 1-ODN and mitomycin against NCl-H460 human large cell lung carcinomas also ... v) wherein said cancer is lung carcinoma and said chemotherapeutic agent is mitomycin.. 3. The method according to claim 2 ...
  http://www.patentgenius.com/patent/5744460.html
*  Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung...
Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life.J Clin ... Non-small Cell Lung Cancer Collaborative Group. .Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data ... Medical Research Council Lung Cancer Working Party. .Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council ... Medical Research Council Lung Cancer Working Party. .Randomized trial of palliative two-fraction versus more intensive 13- ...
  http://www.bmj.com/content/325/7362/465
*  Predicting Tumor Responses to Mitomycin C on the Basis of DT-Diaphorase Activity or Drug Metabolism by Tumor Homogenates:...
... relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res., 52: 4752-4757, 1992. ... Pan S-S., Andrews P. A., Glover C. J., Bachur N. R. Reductive activation of mitomycin C and mitomycin C metabolites by NADPH- ... Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C induced DNA ... and a broad spectrum of response exists with lung tumors (T/C ,10% in five of seven non-small cell lung cancer) being ...
  http://cancerres.aacrjournals.org/content/60/22/6384
*  Mitomycin-C - UNM Comprehensive Cancer Center
Patients will also have their lung function monitored, as problems of the lung may result due to treatment with mitomycin. In ... How is mitomycin given (administered)? Mitomycin may be administered into a vein (intravenous) and the dose depends on several ... Generic Name: Mitomycin (mye-toe-MYE-sin), Mitomycin-C, MTC. Trade Name: Mutamycin® ... Non-Small Cell Lung Cancer *Stage I Non-Small Cell Lung Cancer ... Small Cell Lung Cancer *Extensive Small Cell Lung Cancer. * ...
  http://cancer.unm.edu/2009/04/28/mitomycin-c-2/
*  Mitomycin - Chemotherapy Drugs - Chemocare
Mitomycin (Mutamycin) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatment of ... Lung problems: pneumonitis, rarely pulmonary fibrosis. The incidence of lung problems increases with age and pre-existing lung ... Mutamycin is the trade name for mitomycin. MTC and Mitomycin-C are other names for mitomycin. In some cases, health care ... Your health care professional will monitor the amount of mitomycin you receive as well as your lung function during treatment. ...
  http://chemocare.com/chemotherapy/drug-info/Mitomycin.aspx
*  FANCL - Wikipedia
2007). "Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells". Cancer Biol. Ther. 5 (12): ...
  https://en.wikipedia.org/wiki/FANCL
*  Nanoparticulate Drug Delivery System |authorSTREAM
13) Yoshioka T, Hashida M, Muranishi S, Sezaki H. Specific delivery of mitomycin C to the liver, spleen, and lung: nano- and ...
  http://www.authorstream.com/Presentation/aSGuest128957-1355204-satish-ppt/
*  CYB5R3 - Wikipedia
... relationship to the response of lung tumor xenografts to mitomycin Cł". Cancer Research. 52 (17): 4752-7. PMID 1324793. Shirabe ... "Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: ...
  https://en.wikipedia.org/wiki/CYB5R3
*  Study of Arsenic Trioxide in Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Need for treatment with chemotherapy (within 4 weeks; 6 weeks for nitrosoureas or mitomycin C); radiotherapy or biologic agents ... Lung Cancer Cancer of Lung Pulmonary Cancer Pulmonary Neoplasms Carcinoma, Small Cell Drug: Arsenic Trioxide Phase 2 ... Lung Neoplasms. Small Cell Lung Carcinoma. Carcinoma, Small Cell. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by ... Study of Arsenic Trioxide in Small Cell Lung Cancer. The safety and scientific validity of this study is the responsibility of ...
  https://clinicaltrials.gov/ct2/show/NCT01470248
*  Chemotherapy-Related Drug-Induced Lung Injury
Like bleomycin and mitomycin, Actinomycin D may cause pulmonary toxicity in the form of acute or subacute interstitial lung ... Mitomycin-C. Mitomycin-related pulmonary toxicity occurs in 3-12% of patients and is associated with a wide variety of ... Pulmonary toxicity due to carmustine includes interstitial lung disease and pneumothorax.. *. Interstitial lung disease due to ... Patients with non-small cell lung cancer (NSCLC) are more likely to develop interstitial lung disease than patients with other ...
  https://www.endocrinologyadvisor.com/pulmonary-medicine/chemotherapy-related-drug-induced-lung-injury/article/625559/
*  Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer - Full Text View -...
Mitomycin C/nitrosoureas =, 42 days prior to registration. *Immunotherapy =, 28 days prior to registration ... Recurrent Non-small Cell Lung Cancer Squamous Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell ... Lung Neoplasms. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung Diseases. Respiratory Tract ... Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer. The safety and ...
  https://clinicaltrials.gov/ct2/show/NCT01383668?cond=%22Carcinoma%2C+Non-Small-Cell+Lung%22&rank=17
*  Robert W. Carlson | Stanford Medicine Profiles
HIGH-DOSE CISPLATIN AND MITOMYCIN-C IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY OF THE NORTHERN-CALIFORNIA- ... LATE CONSOLIDATIVE RADIATION-THERAPY IN THE TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER CANCER Carlson, R. W., Sikic, B. ... BLEOMYCIN, MITOMYCIN, AND CISPLATIN THERAPY FOR ADVANCED SQUAMOUS CARCINOMA OF THE UTERINE CERVIX - A PHASE-II STUDY OF THE ... The mean cisplatin and mitomycin C delivered dose intensities in this study were 45 mg/m2 per week (90% of the projected dose) ...
  https://med.stanford.edu/profiles/robert-carlson
*  Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer - Full Text View - ClinicalTrials.gov
... greater than 6 weeks from mitomycin C; and greater than 8 weeks from prior UCN01 treatment. ... Lung Neoplasms Ovarian Neoplasms Cervix Neoplasms Renal Neoplasms Drug: docetaxel Drug: tariquidar Other: 99mTc-sestamibi ... Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer. The safety and scientific validity of ... Lung Neoplasms. Ovarian Neoplasms. Kidney Neoplasms. Uterine Neoplasms. Genital Neoplasms, Female. Urogenital Neoplasms. ...
  https://clinicaltrials.gov/ct2/show/NCT00069160?term=Cervical+Cancer%3A+Clinical+Trials&rank=17
*  Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer - Full Text View - ClinicalTrials.gov
... greater than 6 weeks from mitomycin C; and greater than 8 weeks from prior UCN01 treatment. ... Lung Neoplasms Ovarian Neoplasms Cervix Neoplasms Renal Neoplasms Drug: docetaxel Drug: tariquidar Other: 99mTc-sestamibi ... Lung Diseases. Respiratory Tract Diseases. Endocrine Gland Neoplasms. Ovarian Diseases. Adnexal Diseases. Endocrine System ... Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer. This study has been completed. ...
  https://clinicaltrials.gov/show/NCT00069160
*  ISRCTN - ISRCTN57675565: A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in...
Lung (non-small cell) cancer Intervention. Cisplatin 50 mg/m2 Mitomycin-C 8 mg/m^2 intravenous (iv) day one. Vinblastine 6 mg/m ... A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell ... A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell ...
  http://www.isrctn.com/ISRCTN57675565
*  Mithramycin for Lung, Esophagus, and Other Chest Cancers - Full Text View - ClinicalTrials.gov
At least six weeks must have elapsed between mitomycin C or nitrosourea treatment. ... Mithramycin for Lung, Esophagus, and Other Chest Cancers. The safety and scientific validity of this study is the ... Lung Cancer Esophageal Cancer Mesothelioma Gastrointestinal Neoplasms Breast Cancer Drug: Mithramycin Phase 2 ... IV mithramycin in patients with primary lung cancer (CLOSED). Drug: Mithramycin 30 mcg/kg IV over 6 h once daily for 7 days, to ...
  https://clinicaltrials.gov/show/NCT01624090
*  Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs - Full Text View - ClinicalTrials.gov
No prior mitomycin, bleomycin, or nitrosoureas. *No other concurrent systemic chemotherapy. Endocrine therapy:. *Not specified ... stage IIIB non-small cell lung cancer. stage IV non-small cell lung cancer. pulmonary carcinoid tumor. lung metastases. ... recurrent non-small cell lung cancer. extensive stage small cell lung cancer. recurrent small cell lung cancer. advanced ... Lung Diseases. Respiratory Tract Diseases. Adenoma. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. ...
  https://clinicaltrials.gov/ct2/show/NCT00020124
*  Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer - Full Text View - ClinicalTrials.gov
At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) ... Adenocarcinoma of the Lung Bronchoalveolar Cell Lung Cancer Non-small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer ... Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Adenocarcinoma. Adenocarcinoma, Bronchiolo-Alveolar. Respiratory Tract ... Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Drug: bortezomib Phase 2 ...
  https://clinicaltrials.gov/ct2/show/NCT00118144?recr=Open&cond=%22Lung+Neoplasms%22&rank=11
*  Mediastinal-, Lungen- und Pleuratumoren | Springer for Research & Development
1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life ... Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM (1988) Mitomycin, ifosfamide, and cis-platin in non-small cell lung cancer ... Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer. A meta-analysis using updated ... Strauss MJ, Moran RE, Shakney SE (1983) Growth characteristics of lung cancer. In: Srauss MJ (ed) Lung cancer.Clinical ...
  https://rd.springer.com/chapter/10.1007/978-3-662-10475-0_27
*  Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer ...
Use of any nitrosourea or mitomycin-C within 6 weeks of screening ... Non-Small Cell Lung Cancer Cancer Lung Neoplasms Oncology Solid ... Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Thrombocytopenia. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by ... Advanced Non-Small Cell Lung Cancer. Chemotherapy Induced Thrombocytopenia. CIT. NSCLC. Stage IIIB NSCLC. Stage IV NSCLC. ... Lung Diseases. Respiratory Tract Diseases. Carcinoma, Bronchogenic. Bronchial Neoplasms. Blood Platelet Disorders. Hematologic ...
  https://clinicaltrials.gov/ct2/show/NCT00413283
*  Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non...
Arm II: Patients receive mitomycin IV, ifosfamide IV over 3 hours, and cisplatin IV over 1 hour on day 1 OR mitomycin IV, ... Compare the one and two year survival of patients with inoperable advanced non-small cell lung cancer treated with paclitaxel ... A Randomized Phase III Comparative Study of Paclitaxel With Carboplatin Versus Mitomycin, Ifosfamide, Cisplatin (MIC) ... Chemotherapy in Inoperable Advanced Stage Non-Small Cell Lung Cancer. Brief Summary RATIONALE: Drugs used in chemotherapy use ...
  https://clinicaltrials.gov/ct2/show/record/NCT00004887
*  A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. - Full Text View...
2 weeks for palliative radiotherapy to bones, 6 weeks for nitrosoureas and mitomycin ... Lung Neoplasms. Carcinoma, Non-Small-Cell Lung. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. ... A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.. The safety and ... ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand- ...
  https://clinicaltrials.gov/ct2/show/study/NCT01124864?view=results
*  Plus it
Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30. ... Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin ... In clinical trials, normal tissue late effects in soft tissues, lung, bone, and spinal cord were not found to be increased ... The non-small cell lung carcinoma cell line H460 was obtained from American Type Culture Collection and was grown in ...
  http://clincancerres.aacrjournals.org/content/15/8/2927
*  Overview and State of the Art in the Management of Lung Cancer | Cancer Network | The Oncology Journal
Non-small-cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancers, while small-cell lung cancer (SCLC) accounts ... Lung cancer is a major health problem worldwide. ... mitomycin, vindesine, and cisplatin in. unresectable stage III ... Small-Cell Lung Cancer. Small-cell lung cancer accounts for. 15% to 20% of lung cancer diagnosed. in the United States. Small- ... Non-small-cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancers, while small-cell lung cancer (SCLC) accounts ...
  http://www.cancernetwork.com/review-article/overview-and-state-art-management-lung-cancer
*  Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or...
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered ... Lung Neoplasms. Small Cell Lung Carcinoma. Respiratory Tract Neoplasms. Thoracic Neoplasms. Neoplasms by Site. Neoplasms. Lung ... A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. ... Recurrent Small Cell Lung Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: obatoclax mesylate Drug: topotecan ...
  https://clinicaltrials.gov/ct2/show/NCT00521144